Quantum Genomics - Phase IIb QUORUM results
Quantum Genomics has reported the results of the Phase IIb QUORUM study at the European Society of Cardiology. Unfortunately, the primary endpoint of change from baseline in the left ventricular ejection fraction (LVEF) after a 12-week treatment was missed, with essentially no difference between the firibastat 500mg BID arm and the ramipril 5mg BID arm (there was a slight trend in favour of ramipril with a p-value of 0.789). The company noted a trend in firibastat’s favour in patients with an LVEF of less than 50%, but this was also not significant. The company has stated it is moving forward into Phase III in severe patients.Quantum Gernomics is a biotechnology firm specializing in the development of innovative drugs to combat cardiovascular diseases. Run by professionals in creating and managing technological start-ups and drug development, as well as researchers and inventors, Co. has established contractual relations with institutions of academic excellence in France (Inserm, CollA
Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisors and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.
.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.